Skip to main content
SpringerLink
Log in

Safety Considerations in Treating Concomitant Diseases in Patients with Asthma

  • Review Article
  • Drug Safety Concept
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

The treatment for asthma usually involves a combination of drugs used for bronchodilation and to treat underlying airway inflammation. When asthma is severe, the regimen used to treat asthma can become quite complicated, often using as many as 3 or 4 separate pharmacological agents. As patients with asthma get older, their medication regimen can become even more complex with the development of numerous other age-related diseases requiring their own list of medications. Diseases of the joints, diseases of the eye, cardiovascular disease, neurological disease and urological problems represent the most common conditions that patients develop, at times needing medications which might interfere with asthma management. Many of these diseases require the use of nonsteroidal antiinflammatory agents, well known to provoke wheezing in patients with intrinsic asthma, and diseases of the eye and cardiovascular system frequently require use of β-blockers which can cause or exacerbate asthma. Managing patients with asthma who have other diseases requires constant supervision of their medication usage and careful and cautious review of the entire list of medications at each presentation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dodge RR, Burrows B. The prevalence and incidence of asthma and asthma-like symptoms in a general population sample. Am Rev Respir Dis 1980 Oct; 122: 567–75

    PubMed  CAS  Google Scholar 

  2. Yunginger JW, Reed CE, O’Connell EJ, et al. A community-based study of the epidemiology of asthma. Am Rev Respir Dis 1992 Oct; 146: 888–94

    PubMed  CAS  Google Scholar 

  3. Brandt KD. Osteoarthritis in principles of internal medicine. 13th ed. New York: McGraw-Hill Inc., 1994: 1692–8

  4. Cicuttini FM, Spector TD. Osteoarthritis in the aged: epidemiological issues and optimal management. Drugs Aging 1995 May; 6(5): 409–29

    PubMed  CAS  Google Scholar 

  5. Nesher G, Moore TL. Rheumatoid arthritis in the aged: incidence and optimal management. Drugs Aging 1993 Nov–Dec; 3(6): 487–501

    PubMed  CAS  Google Scholar 

  6. Anti-arthritic medication usage: United States, 1991. Stat Bul Metrop Ins Co. 1992;73: 25-34

  7. McDonald JR, Mathison DA, Stevenson DD. Aspirin intolerance in asthma: detection by oral challenge. J Allergy Clin Immunol 1972; 50: 198–207

    PubMed  CAS  Google Scholar 

  8. Settipane GA. Asthma, aspirin intolerance and nasal polyps. N Engl Reg Allergy Proc 1986; 7: 32–7

    PubMed  CAS  Google Scholar 

  9. Chafee FH, Settipane GA. Aspirin intolerance: frequency in an allergic population. J Allergy Clin Immunol 1974; 53: 193–9

    Google Scholar 

  10. Iamandescu IB. NSAID-induced asthma: peculiarities related to background and association with other non-etiological agents. Allergol Immunopathol 1989; 6: 285–90

    Google Scholar 

  11. Settipane RA, Constantine HP, Settipane GA. Aspirin intolerance and recurrent urticaria in normal adults and children. Allergy 1980; 35: 149–54

    PubMed  CAS  Google Scholar 

  12. Bianca M, Perez E, Garcia JJ, et al. Angioedema and IgE antibodies to aspirin: a case report. Ann Allergy 1989; 62: 295–8

    Google Scholar 

  13. Stevenson DD. Aspirin desensitization. NER Allergy Proc 1986; 7(2): 101–4

    PubMed  CAS  Google Scholar 

  14. Stevenson DD. Diagnosis, prevention and treatment of adverse reactions to aspirin and nonsteroidal antiinflammatory drugs. J Allergy Clin Immunol 1984; 74: 617–22

    PubMed  CAS  Google Scholar 

  15. Sampter M, Beers RF. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med 1968; 68: 975–83

    Google Scholar 

  16. Tan Y, Collins-Williams C. Aspirin-induced asthma in children. Ann Allergy 1982; 48: 1–5

    PubMed  CAS  Google Scholar 

  17. Lumry WR, Curd JG, Stevenson DD. Aspirin-sensitive asthma and rhinosinusitis: current concepts and recent advances. Ear Nose Throat J 1984; 63: 66–80

    PubMed  CAS  Google Scholar 

  18. Szczeklik A, Nizankowska E, Dukes MMG. Drug-induced asthma and bronchospasm. In: Akoun GM, White JP, editors. Drug-induced disorders. Vol. 3. Amsterdam: Elsevier, 189-209

  19. McDonald JR, Mathison DA, Stevenson DD. Aspirin intolerance in asthma: detection by oral challenge. J Allergy Clin Immunol 1972; 50: 198–207

    PubMed  CAS  Google Scholar 

  20. Phillips GD, Ford R, Holgate ST. Inhaled lysine-aspirin as a bronchoprovocation procedure in aspirin-sensitive asthma: its repeatability, absence of a late-phase reaction, and the role of histamine. J Allergy Clin Immunol 1989; 84: 232–41

    PubMed  CAS  Google Scholar 

  21. Schapowal AG, Simon HU, Schmitz-Schumann M, et al. Phenomenology, pathogenesis, diagnosis and treatment of aspirin-sensitive rhinosinusitis. Acta Otorhinolaryngol Belg 1995; 49: 235–50

    PubMed  CAS  Google Scholar 

  22. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesia to asthma attacks in aspirin-sensitive patients. BMJ 1975; 1: 67–9

    PubMed  CAS  Google Scholar 

  23. Morris HG, Sherman NA, McQuain C, et al. Effects of salsalate (nonacetylated salicylate) and aspirin on serum prostaglandins in humans. Ther Drug Monit 1985; 7(4): 435–8

    PubMed  CAS  Google Scholar 

  24. Stevenson DD, Lewis RA. Proposed mechanisms of aspirin sensitivity reactions. J Allergy Clin Immunol 1987; 80: 788–90

    PubMed  CAS  Google Scholar 

  25. Sladek K, Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J 1993; 6: 391–9

    PubMed  CAS  Google Scholar 

  26. Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary LTE4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991; 143: 1025–9

    PubMed  CAS  Google Scholar 

  27. Arm JP, O’Hickey SP, Spur BW, et al. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin induced asthma. Am Rev Respir Dis 1989; 140: 148–53

    PubMed  CAS  Google Scholar 

  28. Christie PE, Smith CM, Lee TH. The potent and selective sul-fidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144: 957–8

    PubMed  CAS  Google Scholar 

  29. Dahlen B, Kumlin M, Margolskee DJ, et al. The leukotriene-re-ceptor antagonist MK-0679 blocks airway obstruction induced by bronchial provocation with lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993; 7: 1018–26

    Google Scholar 

  30. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447–51

    PubMed  CAS  Google Scholar 

  31. Nasser S, Christie PE, Pfister R, et al. Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects. Thorax 1996 Jan; 51: 64–70

    PubMed  CAS  Google Scholar 

  32. Chen AH, Bennett CR. Ketorolac-induced bronchospasm in an aspirin-intolerant patient. Anesthesia Progress 1994; 41: 102–7

    PubMed  CAS  Google Scholar 

  33. Stevenson DD, Pleskow WW, Simon RA, et al. Aspirin-sensitive rhinosinusitis asthma: a double blind crossover study of treatment with aspirin. J Allergy Clin Immunol 1984; 73: 500–7

    PubMed  CAS  Google Scholar 

  34. Sweet JM, Stevenson DD, Simon RA. et al. Long-term effects of aspirin desensitization treatment for aspirin-sensitive rhino-sinusitis-asthma. J Allergy Clin Immunol 1990; 85: 59–65

    PubMed  CAS  Google Scholar 

  35. Nasser SMS, Bell GS, Foster S, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 1994; 49: 749–56

    PubMed  CAS  Google Scholar 

  36. Sharir M. Exacerbation of asthma by topical diclofenac. Arch Ophthalmol 1997 Feb; 115: 294–5

    PubMed  CAS  Google Scholar 

  37. Sitenga GL, Ing EB, Van Dellen RG, et al. Asthma caused by topical application of ketorolac. Ophthalmology 1996 Jun; 103: 890–2

    PubMed  CAS  Google Scholar 

  38. Wray SH, Slamovits TL, Bürde RM. Diseases of the optic nerve. In: Principles of internal medicine. 13th ed. New York: McGraw-Hill, Inc., 1994: 104–6

    Google Scholar 

  39. Frishman WH, Fuksbrumer MS, Tannenbaum M. Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension. J Clin Pharmacol 1994 Aug; 34: 795–803

    PubMed  CAS  Google Scholar 

  40. Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol 1982; 26: 207–12

    PubMed  CAS  Google Scholar 

  41. McNeill RS. Effect of a beta-adrenergic blocking agent, propranolol on asthmatics. Lancet 1964; II: 1101

    Google Scholar 

  42. Fraley DS, Bruns FJ, Segel DP, et al. Propranolol-related bronchospasm in patients without a history of asthma. S Med J 1980; 73: 238–40

    CAS  Google Scholar 

  43. McNeill RS, Ingram CG. Effect of propranolol on ventilatory function. Am J Cardiol 1966; 18: 473–5

    PubMed  CAS  Google Scholar 

  44. Committee on Safety of Medicines. Fatal bronchospasm associated with beta-blockers. Current Problems in Phar-macovigilance 1987; No. 20

  45. Anderson EG, Calcraft B, Jarialla AG, et al. Persistent asthma after treatment with beta-blocking drugs. Br J Dis Chest 1979; 73: 407–8

    PubMed  CAS  Google Scholar 

  46. Craig DO, Richerson HB, Moeckli J. Problem drugs for the patient with asthma. Compr Ther 1996; 22: 339–44

    PubMed  CAS  Google Scholar 

  47. Hannaway PJ, Hopper GDK. Severe anaphylaxis and drug-induced beta-blockade [letter]. N Engl J Med 1983; 308: 1536

    PubMed  CAS  Google Scholar 

  48. Hamilton G. Severe adverse reactions to urography in patients taking β-adrenergic blocking agents. Can Med Assoc J 1985; 133: 122

    PubMed  CAS  Google Scholar 

  49. Jacobs RL, Rake GW, Fournier DC, et al. Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade. J Allergy Clin Immunol 1981; 68: 125–7

    PubMed  CAS  Google Scholar 

  50. Berkelman RL, Finton RJ, Elsea WR. Beta-adrenergic antagonists and fatal anaphylactic reactions to oral penicillin [letter]. Ann Intern Med 1986; 104: 134

    PubMed  CAS  Google Scholar 

  51. Hiatt WR, Wolfel EE, Stoll S, et al. Beta-2 adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol. Clin Pharmacol Ther 1985; 37: 2–6

    PubMed  CAS  Google Scholar 

  52. Lands AM, Luduena FP, Buzzo JH. Differentiation of receptors responsive to isoproterenol. Life Sci 1967; 6: 2241–9

    PubMed  CAS  Google Scholar 

  53. Brodde OE, Karad K, Zerkowski HR, et al. Coexistence of β1-and β2-adrenoceptors in human right atrium. Circ Res 1983; 53: 752–8

    PubMed  CAS  Google Scholar 

  54. Pringle TH, Riddell JG. The cardioselectivity of beta adrenoceptor antagonists. Pharmacacol Ther 1990; 45: 39–68

    CAS  Google Scholar 

  55. Carstairs JR, Nimmo AJ, Barnes PJ. Autoradiographic visualization of beta-adrenoceptor subtypes inhuman lung. Am Rev Respir Dis 1985; 132: 541–7

    PubMed  CAS  Google Scholar 

  56. Barnes PJ. Beta-adrenoceptors in lung tissue. In: Morley J, editor. Perspectives in asthma: beta2-adrenoceptors in asthma. London: Academic Press, 1984; 67–95

    Google Scholar 

  57. Motulsky JJ, Insel P. Adrenergic receptors in man: direct identification, physiologic regulation and clinical alterations. N Engl J Med 1982; 307: 18–29

    PubMed  CAS  Google Scholar 

  58. Galant SP, Duriseti L, Underwood S, et al. Decreased beta-adrenergic receptors on polymorphonuclear leukocytes after adrenergic therapy. N Engl J Med 1978; 299: 933–6

    PubMed  CAS  Google Scholar 

  59. Aarons RD, Nies AS, Gal J, et al. Elevation of β-adrenergic receptor density: I. human lymphocytes after propranolol administration. J Clin Invest 1980; 65: 949–57

    PubMed  CAS  Google Scholar 

  60. Barnes PJ. Endogenous catecholamines and asthma. J Allergy Clin Immunol 1986; 77: 791–5

    PubMed  CAS  Google Scholar 

  61. Meurs H, Kauffman HF, Koëter GH, et al. Regulation of the beta-receptor-adenylate cyclase system in lymphocytes of allergic patients with asthma: possible role for protein kinase C in allergen-induced nonspecific refractoriness of adenylate cyclase. J Allergy Clin Immunol 1987; 80: 326–39

    PubMed  CAS  Google Scholar 

  62. Sano Y, Watt G, Townley RG. Decreased mononuclear cell beta-adrenergic receptors in bronchial asthma: parallel studies of lymphocyte and granulocyte desensitization. J Allergy Clin Immunol 1983; 72: 495–503

    PubMed  CAS  Google Scholar 

  63. Nijkamp FP, Henricks PAJ. Receptors in airway disease: beta-adrenoceptors in lung inflammation. Am Rev Respir Dis 1990; 141: S145–50

    PubMed  CAS  Google Scholar 

  64. Rhoden KJ, Meldrum LA, Barnes PJ. Inhibition of cholinergic neurotransmission in human airway by β2-adrenoceptors. J Appl Physiol 1988; 65: 700–6

    PubMed  CAS  Google Scholar 

  65. Fryer AD, Maclagan J. Muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig. Br J Pharmacol 1984; 83: 973–8

    PubMed  CAS  Google Scholar 

  66. Minette PAH, Lammers JW, Dixon CMS, et al. A muscarinic agonist inhibits reflex bronchoconstriction in normal but not in asthmatic subjects. J Appl Physiol 1989; 67: 2461–5

    PubMed  CAS  Google Scholar 

  67. Barnes PJ, Minette P, Maclagan J. Muscarinic receptor subtypes in airways. Trends Pharmacol Sci 1988; 9: 412–6

    PubMed  CAS  Google Scholar 

  68. Fryer AD, Wills-Karp M. Dysfunction of M2-muscarinic receptors in pulmonary parasympathetic nerves after antigen challenge. J Appl Physiol 1991; 71: 2255–61

    PubMed  CAS  Google Scholar 

  69. Elbon CL, Jacoby DB, Fryer AD. Pretreatment with an antibody to interleukin-5 prevents loss of pulmonary M2-muscarinic receptor function in antigen-challenged guinea pigs. Am J Respir Cell Mol Biol 1995; 12: 320–8

    PubMed  CAS  Google Scholar 

  70. Lefort J, Nahori MA, Ruffiè C, et al. In vivo neutralization of eosinophil-derived major basic protein inhibits antigen-induced bronchial hyperreactivity in sensitized guinea pigs. J Clin Invest 1996; 97: 1117–21

    PubMed  CAS  Google Scholar 

  71. Fratto C. Provocation of bronchospasm by eye drops. Ann Intern Med 1978: 88: 362

    PubMed  CAS  Google Scholar 

  72. Dannenberg AL, Garrison RJ, Kannel WB. Incidence of hypertension in the Framingham study. Am J Publ Health 1988; 78: 676–9

    CAS  Google Scholar 

  73. Kuller L, Borhani N, Furberg C, et al. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol 1994; 139: 1164–79

    PubMed  CAS  Google Scholar 

  74. Lawrence DS, Sahay JN, Chatterjee SS, et al. Beta-blockers in asthma. Drugs 1983; 25 Suppl. 2: 232–6

    CAS  Google Scholar 

  75. Breckenridge A. Which beta-blocker? BMJ 1983; 286: 1085–7

    PubMed  CAS  Google Scholar 

  76. Nair N, Townley RG, Bewtra A, et al. Safety of nifedipine in subjects with bronchial asthma and COPD. Chest 1984; 86: 515–8

    PubMed  CAS  Google Scholar 

  77. Kaplan NM. Maximally reducing cardiovascular risk in the treatment of hypertension. Ann Intern Med 1988; 109: 36–40

    PubMed  CAS  Google Scholar 

  78. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429–35

    Google Scholar 

  79. Boulet LP, Milot J, Lamprom N, et al. Pulmonary function and airway responsiveness during long term therapy with Captopril. JAMA 1989; 261: 413–6

    PubMed  CAS  Google Scholar 

  80. Gibson GR. Enalapril-induced cough. Arch Intern Med 1989; 149: 2701–3

    PubMed  CAS  Google Scholar 

  81. Roth A. Chronic cough caused by angiotensin converting enzyme inhibitors. Ann Allergy 1990; 64: 47–8

    PubMed  CAS  Google Scholar 

  82. O’Hollaren MT, Porter GA. Angiotensin converting enzyme inhibitors and the allergist. Ann Allergy 1990; 64: 503–6

    PubMed  Google Scholar 

  83. Gianos ME, Klaustermeyer WB, Kurohara M, et al. Enalapril induced angioedema. Am J Emerg Med 1990; 8: 124–6

    PubMed  CAS  Google Scholar 

  84. Sabroe RA, Black AK. Angiotensin-converting enzyme (ACE) inhibitors and angioedema. Br J Dermatol 1997; 136: 153–8

    PubMed  CAS  Google Scholar 

  85. Mullins RJ. Shanahan TM, Dobson RT. Visceral angioedema related to treatment with an ACE inhibitor. Med J Aust 1996; 165: 319–21

    PubMed  CAS  Google Scholar 

  86. Gabb GM, Ryan P, Wing LM, et al. Epidemiological study of angioedema and ACE inhibitors. Aust N Z J Med 1966; 26: 777–82

    Google Scholar 

  87. Pillans PI, Coulter DM, Black P. Angiedema and urticaria with angiotensin converting enzyme inhibitors. Eur J Clin Pharm 1996; 51: 123–6

    CAS  Google Scholar 

  88. Brown NJ, Ray WA, Snowden M. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60: 8–13

    PubMed  CAS  Google Scholar 

  89. Agostoni A, Cicardi M. Contraindications to the use of ACE inhibitors in patients with C1 esterase inhibitor deficiency [letter]. Am J Med 1991; 90: 278

    PubMed  CAS  Google Scholar 

  90. Zimet I. Management of hypertension in the asthmatic patient. Chest 1983; 83 Suppl.: 392–5

    Google Scholar 

  91. Waters WE, O’Connor PJ. Prevalence of migraine. J Neurol Neurosurg Psychiatr 1975; 38: 613–6

    PubMed  CAS  Google Scholar 

  92. Capobianco DJ, Cheshire WP, Campbell JK. An overview of the diagnosis and pharmacologic treatment of migraine. Mayo Clinic Proceedings 1996; 71: 1055–66

    PubMed  CAS  Google Scholar 

  93. Gleiter CH, Deckert J. Adverse CNS-effects of beta-adrenoceptor blockers. Pharmacopsychiatry 1996; 29: 201–11

    PubMed  CAS  Google Scholar 

  94. Doughty MJ, Lyle WM. Medications used to prevent migraine headaches and their potential ocular adverse effects. Optometry Vis Sci 1995; 72: 879–91

    CAS  Google Scholar 

  95. Mealy K, Ngeh N, Gillen P, et al. Propranolol reduces the anxiety associated with day case surgery. Eur J Surg 1996; 162: 11–4

    PubMed  CAS  Google Scholar 

  96. Harris GC, Aston-Jones G. Beta-adrenergic antagonists attenuate withdrawal anxiety in cocaine-and morphine-dependent rats. Psychopharmacology 1993; 113: 131–6

    PubMed  CAS  Google Scholar 

  97. Lefkowitz RJ, Hoffman BB, Taylor P. Cholinergic Transmission. Goodman and Gilman s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill Inc., 1996: 115–20

    Google Scholar 

  98. Lamid S, Lohaus GH, Gokulananda U. Bethanechol (Ure-cholin) and bronchoconstriction. Wis Med J 1982; 81: 32

    PubMed  CAS  Google Scholar 

  99. Lang DM, Alpern MB, Visintainer PF, et al. Elevated risk of anaphylactoid reaction from radiographic contrast media is associated with both β-blocker exposure and cardiovascular disorders. Arch Intern Med 1993; 153: 2033–40

    PubMed  CAS  Google Scholar 

  100. Bagg MNJ, Horwitz TA, Bester L. Comparison of patient responses to high- and low-osmolality contrast agents injected intravenously. Am J Radiol 1986; 147: 185–7

    CAS  Google Scholar 

  101. Lasser EC, Berry CC, Tainer LB, et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med 1987; 317: 845–9

    PubMed  CAS  Google Scholar 

  102. Lin MS, Tanner E, Lynn J, et al. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy 1993; 71: 557–62

    PubMed  CAS  Google Scholar 

  103. Reid MJ, Lockey RF, Turkeltaub PC, et al. Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol 1993; 92: 6–15

    PubMed  CAS  Google Scholar 

  104. Pratter MR, Bartter TC, Dubois J. Bronchodilator reversal of bronchospasm and symptoms incurred during methacholine bronchoprovocation challenge. Documentation of safety and time course. Chest 1993; 104: 1342–5

    PubMed  CAS  Google Scholar 

  105. deMey, C, Enterling D, Ederhof M, et al. Transdermal delivery of mepindolol and propranolol in normal man. Arzneimittelforschung 1989; 39: 1508–12

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic and Graduate School of Medicine, 200 First Street Southwest, Rochester, Minnesota, 55905, USA

    Loren W. Hunt

Authors
  1. Loren W. Hunt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hunt, L.W. Safety Considerations in Treating Concomitant Diseases in Patients with Asthma. Drug-Safety 18, 357–368 (1998). https://doi.org/10.2165/00002018-199818050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199818050-00005

Keywords

Search

Navigation